ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics

SAN DIEGO, June 22, 2026 /PRNewswire/ — ChemDiv, Inc. (www.chemdiv.com), a global provider of integrated drug discovery solutions, today announced significant milestones achieved through its proprietary central nervous system (CNS) focused drug discovery platform. The ChemDiv-built platform has…

Read the full release →

News provided by PR Newswire.